title: Basing approval of drugs for type 2 diabetes on real world outcomes.
authors.affiliation: Section of Clinical Medicine and Ageing, University of Sussex, Guildford GU2 7PX, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: McGovern
authors.affiliation: St George's Vascular Institute, Division of Cardiovascular Sciences, St George's, University of London, London, UK.
authors.forename: Robert
authors.initials: R
authors.lastname: Hinchliffe
authors.affiliation: Section of Clinical Medicine and Ageing, University of Sussex, Guildford GU2 7PX, UK.
authors.forename: Neil
authors.initials: N
authors.lastname: Munro
authors.affiliation: Section of Clinical Medicine and Ageing, University of Sussex, Guildford GU2 7PX, UK.
authors.forename: Simon
authors.initials: S
authors.lastname: de Lusignan
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval / Q000458:organization & administration*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D007004:Hypoglycemic Agents